UCB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 128.6 EUR | +1.70% |
|
+0.12% | +63.05% |
| 04-11 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
| 04-11 | UCB : Berenberg, Buy, raises its price target | CF |
| Sales 2024 * | 5.62B 6.1B 479B | Sales 2025 * | 6.34B 6.88B 540B | Capitalization | 24.41B 26.48B 2,080B |
|---|---|---|---|---|---|
| Net income 2024 * | 411M 446M 35.01B | Net income 2025 * | 860M 933M 73.27B | EV / Sales 2024 * | 4.63 x |
| Net Debt 2024 * | 1.64B 1.78B 140B | Net Debt 2025 * | 798M 866M 67.98B | EV / Sales 2025 * | 3.98 x |
| P/E ratio 2024 * |
61.5
x | P/E ratio 2025 * |
28.5
x | Employees | 8,767 |
| Yield 2024 * |
1.09% | Yield 2025 * |
1.12% | Free-Float | 61.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on UCB
More press releases
More news
| 1 day | +1.70% | ||
| 1 week | +0.12% | ||
| 1 month | +3.29% | ||
| 3 months | +18.52% | ||
| 6 months | +79.98% | ||
| Current year | +63.05% |
1 week
125.50
128.90
1 month
118.10129.50
Current year
78.72129.50
1 year
65.40129.50
3 years
65.40129.50
5 years
60.18129.50
10 years
54.84129.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 31/05/11 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 57 | 30/06/20 |
| Chief Tech/Sci/R&D Officer | 63 | 30/09/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 27/04/16 | |
Dame Davies
BRD | Director/Board Member | 73 | 31/12/13 |
| Chief Executive Officer | 65 | 31/05/11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.88% | 2 M€ | +10.72% | ||
| 0.72% | 14 M€ | +5.66% | - | |
| 0.72% | 5 M€ | +10.09% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 128.6 | +1.70% | 1,149,866 |
| 30/05/24 | 126.5 | -0.55% | 217,042 |
| 29/05/24 | 127.2 | -0.04% | 208,104 |
| 28/05/24 | 127.2 | -0.70% | 182,616 |
| 27/05/24 | 128.2 | -0.27% | 125,770 |
Real-time Euronext Bruxelles, May 31, 2024 at 04:35 pm
More quotes
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
128.6
EUR
Average target price
126.4
EUR
Spread / Average Target
-1.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +63.05% | 26.47B | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B | |
| -17.66% | 7.32B | |
| +88.73% | 7.14B |
- Stock Market
- Equities
- UCB Stock
